Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Kronos Bio Inc (KRON)

Kronos Bio Inc (KRON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 57,089
  • Shares Outstanding, K 60,094
  • Annual Sales, $ 6,290 K
  • Annual Income, $ -112,670 K
  • EBIT $ -111 M
  • EBITDA $ -111 M
  • 60-Month Beta 1.87
  • Price/Sales 8.92
  • Price/Cash Flow N/A
  • Price/Book 0.45
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.74
  • Most Recent Earnings $-0.27 on 08/08/24
  • Next Earnings Date 11/11/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 257.20% ( +257.20%)
  • Historical Volatility 51.87%
  • IV Percentile 56%
  • IV Rank 12.29%
  • IV High 1,466.97% on 03/15/24
  • IV Low 87.74% on 06/12/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 24
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 145
  • Open Int (30-Day) 188

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.26
  • Number of Estimates 3
  • High Estimate -0.20
  • Low Estimate -0.30
  • Prior Year -0.54
  • Growth Rate Est. (year over year) +51.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8520 +12.68%
on 10/08/24
1.0400 -7.69%
on 09/23/24
-0.0700 (-6.80%)
since 09/20/24
3-Month
0.8520 +12.68%
on 10/08/24
1.4600 -34.25%
on 07/25/24
-0.2900 (-23.20%)
since 07/19/24
52-Week
0.6900 +39.13%
on 05/24/24
1.6000 -40.00%
on 07/16/24
+0.0547 (+6.04%)
since 10/20/23

Most Recent Stories

More News
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors

KRON : 0.9600 (+1.05%)
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease

KRON : 0.9600 (+1.05%)
5 Microcap Stocks With 65% or More Upside Potential

While they do carry higher-than-average risk, these microcaps also offer major upside potential for investors seeking startup-sized returns.

BTBT : 4.13 (+1.98%)
^BTCUSD : 67,683.41 (-0.04%)
ERJ24 : 3,144.04s (-0.63%)
GOEV : 0.9523 (-5.71%)
KRON : 0.9600 (+1.05%)
OGI : 1.7600 (-1.12%)
QBTS : 1.2100 (+3.42%)
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML

/PRNewswire/ -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider...

KRON : 0.9600 (+1.05%)
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML

/CNW/ -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider of...

KRON : 0.9600 (+1.05%)
Kronos Bio Continues to Advance Investigational SYK Inhibitors Entospletinib and Lanraplenib with New Preclinical Data at EHA2022 Congress

Posters include preclinical data on SYK inhibition in combination with targeted agents suggesting evidence of preclinical anti-tumor activity in acute...

KRON : 0.9600 (+1.05%)
Kronos Bio’s Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Featured in Four Poster Presentations at EHA2022 Congress

Posters include preclinical data on SYK inhibition in combination with targeted agents and demonstrate preclinical anti-tumor activity in acute myeloid...

KRON : 0.9600 (+1.05%)
Kronos Bio Presents Preclinical Data on Oral CDK9 Inhibitor KB-0742, Providing Additional Evidence of Potential Efficacy in MYC-Amplified and Transcriptionally Addicted Tumors at AACR

Preclinical data featured in three posters show potential of KB-0742 in triple-negative breast, lung and ovarian cancers, as well as lymphoma and rare,...

KRON : 0.9600 (+1.05%)
Kronos Bio’s Investigational CDK9 Inhibitor KB-0742 to be Featured in Four Preclinical Poster Presentations at American Association for Cancer Research Annual Meeting 2022

Data include results from preclinical studies of KB-0742 in MYC-amplified cancers, including small-cell lung, triple-negative breast and ovarian, as well...

KRON : 0.9600 (+1.05%)
Kronos Bio Announces Participation in Cowen 42nd Annual Health Care Conference

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives...

KRON : 0.9600 (+1.05%)

Business Summary

Kronos Bio Inc. is a clinical-stage biopharmaceutical company. It engages in discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription. Kronos Bio Inc. is headquartered in San Mateo, Calif.

See More

Key Turning Points

3rd Resistance Point 1.0218
2nd Resistance Point 0.9935
1st Resistance Point 0.9767
Last Price 0.9600
1st Support Level 0.9316
2nd Support Level 0.9033
3rd Support Level 0.8865

See More

52-Week High 1.6000
Fibonacci 61.8% 1.2524
Fibonacci 50% 1.1450
Fibonacci 38.2% 1.0376
Last Price 0.9600
52-Week Low 0.6900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar